ECM
CLSD

Endurant Capital Management’s Clearside Biomedical CLSD Stock Holding History

Endurant Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,284
Closed -$580K – 56
2018
Q3 		$580K Buy
6,284
+4,324
+221% +$514K 0.26% 62
2018
Q2 		$314K Buy
+1,960
New +$330K 0.14% 62

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's CLSD Position: Q4 2018 in Review

Endurant Capital Management sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 6,284 shares — an estimated $580K sold.

Endurant Capital Management first reported a position in CLSD in Q2 2018 and held it in 2 quarters. The position peaked at $580K in Q3 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • Endurant Capital Management reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • Endurant Capital Management sold 6,284 Clearside Biomedical shares in Q4 2018, an estimated $580K.
  • Endurant Capital Management first reported a position in Clearside Biomedical in Q2 2018 and held it in 2 quarters.
  • Endurant Capital Management's Clearside Biomedical position peaked at $580K in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Endurant Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.